Novartis relapsing multiple sclerosis drug approved by FDA
The U.S. Food and Drug Administration (FDA) has approved its drug kesimpta for the treatment of relapsing multiple sclerosis, including clinically isolated syndrome, relapsing remitting type and active secondary progressive type. < / P > < p > kesimpta is the first and the only B-cell therapy drug approved for patients to be injected at home, once a month through the sensorready automatic syringe pen.
